Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05391217 · ClinicalTrials.gov registry record

Feasibility of Remote Activity Assessment and PRO Collection Among Transgender Cancer Survivors

A clinical trial of Neoplasms and Chronic Disease, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT05391217 is a study of Neoplasms and Chronic Disease that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 20 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05391217, a study of Neoplasms and Chronic Disease, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

Prospective observational feasibility study to evaluate the role of wearable activity monitors to determine the feasibility and acceptability of remote monitoring using wearable technology and PROs to monitor fatigue and physical function in transgender cancer patients and survivors.

Interventions

  • OTHER Remote assessment of patient reported outcomes and daily activity

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-02-01
Est. Completion 2025-07-01

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT05391217

The ClinicalTrials.gov registry entry for NCT05391217 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Remote assessment of patient reported outcomes and daily activity is the first listed.

NCT05391217 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05391217 about?

NCT05391217 is a clinical study titled "Feasibility of Remote Activity Assessment and PRO Collection Among Transgender Cancer Survivors". Prospective observational feasibility study to evaluate the role of wearable activity monitors to determine the feasibility and acceptability of remote monitoring using wearable technology and PROs to monitor fatigue and physical function in transgender cancer patients and survivors.

What is the current status of trial NCT05391217?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-02-01. Estimated completion is 2025-07-01.

What conditions does trial NCT05391217 study?

This clinical trial studies the following conditions: Neoplasms, Chronic Disease.

What interventions are being tested in trial NCT05391217?

The interventions under investigation include: Remote assessment of patient reported outcomes and daily activity (OTHER).

Who is sponsoring clinical trial NCT05391217?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05391217 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.